GAC - I think the reason for no interest from BP has more to do with the failure of the CEPT programs. When torceptapid blew up for Pfiszer I think there was somewhere around $23 billion of market cap came off of the value over the ensuing month. As each of the other 5 CEPT's failed it took more and more off the value of the big pharmas. It has been a while since I have added it up but it was in the area of $50 to $60 billion of lost value. Celgene has recently gotten whacked for paying to much for unproven technology they purchased in the past as well.

If the science works like the company expects it to there could easily be a line-up of potential buyers that would be more than willing to pay up for proven technology that would have dramatically less chance of putting egg on their face. Think about it, 3 potential blockbusters in one pill. You could put a big dent in a couple of your competitors revenue streams and take a much more prestigious spot in the pharma lineup in just a few short years. That could definitely be attractive to more than one company. It would not surprise me to see some form of CVR at either the SSRA or the Top Line Readout if either is positive although I'm not counting on it.

dyodd

tada